Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Jonat

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
BMC Cancer|August 10, 2010
In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cellsMarion T Weigel, Linda Dahmke, Christian Schem, et al.
Journal of Cancer Research and Clinical Oncology|May 10, 2008
Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effectsChristoph Mundhenke, Marion Tina Weigel, Klarissa Hanja Sturner, et al.
BMC Cancer|January 26, 2013
Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastasesChristian Schem, Dirk Bauerschlag, Sascha Bender, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer GroupManfred Kaufmann, Erika Graf, Walter Jonat, et al.
Breast Cancer Research and Treatment|February 5, 2005
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancerGunter von Minckwitz, Walter Jonat, Peter Fasching, et al.
Anticancer Research|July 2, 2014
Significance of syndecan-1 expression in ductal carcinoma in situ of the breastKatharina Tiemann, Marion Tina Weigel, Ibrahim Alkatout, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|January 16, 2013
Evaluation of two different vacuum-assisted breast biopsy systems: Mammotome(R) system 11G/8G vs. ATEC(R) system 12G/9GBerndt-Michael Order, Philipp J Schaefer, G Peters, et al.
European Journal of Cancer (Oxford, England : 1990)|September 28, 2007
A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93Manfred Kaufmann, Erika Graf, Walter Jonat, et al.
Journal of Bone and Mineral Metabolism|December 2, 2011
Application of ex vivo micro-computed tomography for assessment of in vivo fluorescence and plain radiographic imaging for monitoring bone metastases and osteolytic lesionsSanjay Tiwari, Christian Schem, Ann-Christin Lorenzen, et al.
Lancet (London, England)|August 9, 2005
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialRaimund Jakesz, Walter Jonat, Michael Gnant, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
BMC Cancer|August 10, 2010
In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cellsMarion T Weigel, Linda Dahmke, Christian Schem, et al.
Journal of Cancer Research and Clinical Oncology|May 10, 2008
Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effectsChristoph Mundhenke, Marion Tina Weigel, Klarissa Hanja Sturner, et al.
BMC Cancer|January 26, 2013
Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastasesChristian Schem, Dirk Bauerschlag, Sascha Bender, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer GroupManfred Kaufmann, Erika Graf, Walter Jonat, et al.
Breast Cancer Research and Treatment|February 5, 2005
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancerGunter von Minckwitz, Walter Jonat, Peter Fasching, et al.
Anticancer Research|July 2, 2014
Significance of syndecan-1 expression in ductal carcinoma in situ of the breastKatharina Tiemann, Marion Tina Weigel, Ibrahim Alkatout, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|January 16, 2013
Evaluation of two different vacuum-assisted breast biopsy systems: Mammotome(R) system 11G/8G vs. ATEC(R) system 12G/9GBerndt-Michael Order, Philipp J Schaefer, G Peters, et al.
European Journal of Cancer (Oxford, England : 1990)|September 28, 2007
A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93Manfred Kaufmann, Erika Graf, Walter Jonat, et al.
Journal of Bone and Mineral Metabolism|December 2, 2011
Application of ex vivo micro-computed tomography for assessment of in vivo fluorescence and plain radiographic imaging for monitoring bone metastases and osteolytic lesionsSanjay Tiwari, Christian Schem, Ann-Christin Lorenzen, et al.
Lancet (London, England)|August 9, 2005
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialRaimund Jakesz, Walter Jonat, Michael Gnant, et al.
Pageof 11